Race, insurance type, and stage of presentation among lung cancer patients by Efird, Jimmy T. et al.
a SpringerOpen Journal
Efird et al. SpringerPlus 2014, 3:710
http://www.springerplus.com/content/3/1/710RESEARCH Open AccessRace, insurance type, and stage of presentation
among lung cancer patients
Jimmy T Efird1,2*, Hope Landrine1, Kristin Y Shiue1, Wesley T O’Neal3, Tarun Podder4, Julian G Rosenman5
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The purpose of this study was to determine whether African-American lung cancer patients are diagnosed at a later
stage than white patients, regardless of insurance type. The relationship between race and stage at diagnosis by
insurance type was assessed using a Poisson regression model, with relative risk as the measure of association. The
setting of the study was a large tertiary care cancer center located in the southeastern United States. Patients who
were diagnosed with lung cancer between 2001 and 2010 were included in the study. A total of 717 (31%)
African-American and 1,634 (69%) white lung cancer patients were treated at our facility during the study period.
Adjusting for age, sex, and smoking-related histology, African-American patients were diagnosed at a statistically
significant later stage (III/IV versus I/II) than whites for all insurance types, with the exception of Medicaid. Our results
suggest that equivalent insurance coverage may not ensure equal presentation of stage between African-American
and white lung cancer patients. Future research is needed to determine whether other factors such as treatment
delays, suboptimal preventive care, inappropriate specialist referral, community segregation, and a lack of patient trust
in health care providers may explain the continuing racial disparities observed in the current study.
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Lung cancer is the leading cause of cancer deaths in the
United States, with mortality rates per 100,000 being
higher among African-American (AA) (52.2) than white
(49.2) patients (U.S. Cancer Statistics Working Group
2013; Elk and Landrine 2012). While a decline in lung
cancer mortality has been observed in the general popu-
lation, rates remain high in racial and ethnic minorities
(Berger et al. 2007). Advanced stage at diagnosis is an
important indicator of survival among lung cancer pa-
tients. AA lung cancer patients are more likely to be di-
agnosed at a later stage than whites (Schwartz et al.
2003; Hardy et al. 2009; Halpern et al. 2008). This dis-
parity may be explained by racial differences in health
insurance coverage wherein AAs are more likely to be
underinsured or have no health insurance (Kirby and
Kaneda 2010). Privately insured lung cancer patients* Correspondence: jimmy.efird@stanfordalumni.org
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in any medium, provided the original work is phave been shown to survive longer than those with
Medicaid or no insurance (Biswas et al. 2014). Further-
more, AA patients are less likely to receive preventive
cancer services, education, and appropriate specialist re-
ferral, and are more likely to experience treatment delays
(Felix-Aaron et al. 2005; Esnaola et al. 2008; Bach et al.
1999; Neighbors et al. 2007; Hershman et al. 2009).
In general, cancer patients diagnosed at a later stage
have poorer survival than those diagnosed at earlier stages
(e.g., 5-year survival rate of 4% among patients diagnosed
with late-stage disease compared with 54% among patients
diagnosed with early-stage disease (Ward et al. 2010;
American Cancer Society 2014). Comparable stage at
diagnosis between AA and white lung cancer patients has
been observed within the U.S. Military Health System, a
single payor system (Zheng et al. 2012; Mulligan et al.
2006). However, to our knowledge, no studies of lung can-
cer in a civilian population with multiple payors have ex-
amined stage of presentation by insurance type. The
purpose of this study was to provide further insight into
this unanswered question. We hypothesized that AAs, be-
cause of multiple historic determinants of poor health,Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Patient characteristics (N = 2,351)
Patient characteristics White n (%) AA n (%) P-value†
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patients, regardless of insurance type.Overall 1,634 (70) 717 (31) -
Age (years)
Mean ± SD, Median (IQR) 67 ± 10, 68 (14) 64 ± 10, 64 (14) <0.0001
Sex
Male 981 (60) 491 (68) <0.0001
Female 653 (40) 226 (32)
Histology
Higher smoking risk 718 (44) 260 (36) 0.0005
SCC 514 (31) 207 (29)
SCLC 204 (12) 53 (7)
Lower smoking risk 916 (56) 457 (64)
Adenocarcinoma 461 (28) 236 (33)
LCNEC 54 (3) 21 (3)
Bronchoalveolar 32 (2) 13 (2)
NSCLC NOS 324 (20) 177 (25)
Other 45 (3) 10 (1)
Tobacco use§‡′
Never 139 (9) 58 (8) 0.81
Ever 1,495 (91) 659 (92)
Surgery
No 1,066 (65) 549 (77) <0.0001
Yes 568 (35) 168 (23)Results
A total of 717 (31%) AA and 1,634 (69%) white lung
cancer patients were treated at our center during the
study period (Table 1). AA patients were more likely to
be younger, male, and receive chemotherapy and radi-
ation therapy. White patients were more likely to receive
surgery. AA patients were more likely to have adenocar-
cinoma and non-small cell lung carcinoma not otherwise
specified (NSCLC NOS), and less likely to have squa-
mous cell carcinoma (SCC) and small cell lung carcin-
oma (SCLC) than whites.
Adjusting for age, sex, and smoking-related histology,
AA patients had a marginally, but statistically significant
increased risk (≥14%) of being diagnosed at a later stage
(III/IV versus I/II) than whites for all insurance types, with
the exception of Medicaid (Table 2). An increasing trend
across stage of presentation was observed among AA ver-
sus white lung cancer patients, when the data was strati-
fied by age, sex, and smoking-related histology (Table 3).
Furthermore, AAs presented with an increasing trend for
later stage of lung cancer than whites for Medicare with-
out supplement (adjusted p = 0.015), Medicare with sup-
plement (adjusted p-for-trend = 0.016), and no insurance/
self-pay (adjusted p-for-trend = 0.049) (Table 4).Chemotherapy
No 920 (56) 369 (51) 0.031
Yes 714 (44) 348 (49)
Radiation therapy
No 984 (60) 391 (55) 0.011
Yes 650 (40) 326 (45)
Insurance type‡′
Medicare w/o supplement 424 (26) 283 (39) <0.0001
Medicare with supplement 511 (31) 109 (15)
Medicaid 92 (6) 105 (15)
Private insurance 530 (32) 145 (20)
No insurance/self-pay 77 (5) 75 (10)
†Fisher’s Exact (categorical variables), Exact Deuchler-Wilcoxon (continuous
variables). §Cigarette, cigar, pipe, smokeless (snuff, chew).
‡Missing values were imputed using the expectation-maximization algorithm
(n = 10 simulations).
′Fraction missing information (Tobacco Use = 0.019; Insurance Type = 0.0098).
AA = African-American; LCNEC = large cell neuroendocrine carcinoma; NSCLC
NOS = non-small-cell lung carcinoma not otherwise specified; SCC = squamous
cell carcinoma; SCLC = small cell lung carcinoma; SD = standard deviation;
IQR = Interquartile range.Discussion
Our results support previously published findings that
AA lung cancer patients are more likely to be diagnosed
at a later stage than whites (Yang et al. 2010; Schwartz
et al. 2003; Hardy et al. 2009; Halpern et al. 2008). Add-
itionally, it is uniquely shown that AA lung cancer pa-
tients with similar insurance coverage were diagnosed
with more advanced disease than whites, except for
Medicaid patients. This finding suggests that equivalent
insurance coverage may not ensure equal presentation
of stage between AA and white lung cancer patients.
The impact of race on stage at diagnosis may be re-
lated to factors other than insurance type in the current
study. For example, social exclusion and provider mis-
trust may affect health outcomes for AA patients regard-
less of socioeconomic position (Carpenter et al. 2009;
Hausmann et al. 2008; Williams and Jackson 2005).
Other factors such as socioeconomic status (SES), resi-
dential segregation, and area-level SES also have been
shown to contribute to lung cancer prevalence rates,
stage at diagnosis, quality of care, and survival rates
(Bennett et al. 1998; Hayanga et al. 2013; Landrine et al.
2012; Smith et al. 2012; Hao et al. 2011b, a). However,
the extent to which racial differences in stage at diagno-
sis of lung cancer patients is attributable to the abovesocial determinants, as well as health beliefs, knowledge
and behavior, remains unclear.
In the current study, stage of presentation did not statis-
tically differ between AA and white lung cancer patients
with Medicaid coverage. Possibly, Medicaid represents a
Table 2 Relative risk of an AA patient presenting with Stage III/IV lung cancer by insurance type (N = 2,351)
Type of health
insurance
Stages Relative risk (95% CI)
III/IV I/II Unadjusted† Adjusted model 1†¥ Adjusted model 2₰
n (%) n (%)
All insurance types (n = 2,351)
White 976 (65) 658 (77) 1.0 Referent 1.0 Referent 1.0 Referent
AA 516 (36) 201 (23) 1.20 (1.13-1.28) p < 0.0001 1.19 (1.12-1.27) p < 0.0001 1.17 (1.10-1.24) p < 0.0001
Medicare w/o supplement (n = 707)
White 248 (56) 176 (66) 1.0 Referent 1.0 Referent 1.0 Referent
AA 193 (44) 90 (34) 1.17 (1.04-1.31) p = 0.0077 1.16 (1.03-1.29) p = 0.013 1.15 (1.02-1.28) p = 0.018
Medicare with supplement (n = 620)
White 296 (79) 215 (87) 1.0 Referent 1.0 Referent 1.0 Referent
AA 77 (21) 32 (13) 1.22 (1.06-1.41) p = 0.0061 1.22 (1.05-1.40) p = 0.0073 1.21 (1.05-1.40) p = 0.010
Medicaid (n = 197)
White 59 (44) 33 (53) 1.0 Referent 1.0 Referent 1.0 Referent
AA 76 (56) 29 (47) 1.13 (0.93-1.37) p = 0.22 1.12 (0.92-1.36) p = 0.24 1.14 (0.94-1.37) p = 0.19
Private insurance (n = 675)
White 313 (76) 217 (83) 1.0 Referent 1.0 Referent 1.0 Referent
AA 101 (24) 44 (17) 1.18 (1.04-1.34) p = 0.012 1.16 (1.02-1.32) p = 0.024 1.14 (1.005-1.30) p = 0.042
No insurance/self-pay (n = 152)
White 60 (47) 17 (74) 1.0 Referent 1.0 Referent 1.0 Referent
AA 69 (53) 6 (26) 1.18(1.03-1.35) p = 0.017 1.16 (1.0007-1.33) p = 0.040 1.15 (1.006-1.32) p = 0.041
†Relative risk and 95% confidence intervals (CI) computed using Poisson regression with robust variance estimation.
¥Adjusted for sex and smoking-related histology.
₰Adjusted for age (continuous), sex and smoking-related histology.
AA = African-American.
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race. Medicaid patients presumably have low SES and
equally poor access to care due to low provider acceptance
of this plan (Forrest et al. 2007). In contrast, patients who
did not have health insurance may reflect a marginally
higher socioeconomic position (e.g., working poor) closer
to non-Medicaid coverage. Alternatively, this finding may
represent an unexplained paradox, specific to our patient
population, or chance.
Our findings support earlier research demonstrating
that AA lung cancer patients are less likely to receive
surgery for their disease compared with whites (Bach
et al. 1999; Hardy et al. 2009; Yang et al. 2010; Said et al.
2010). A possible explanation for this finding is that AA
patients are more likely to present with advanced disease
that is not surgically treatable. In general, it is well
known that minorities prioritize health to a lesser de-
gree, postpone seeing a doctor, or do not have a regular
physician, which may have contributed to the later stage
at presentation observed in AA patients.
Lung cancer mortality rates per 100,000 in our region
are consistently higher among male (89.6) and female
(45.5) AAs than male (82.7) and female (35.7) whites
(Rao and Knight 2008). We observed a similar trend for
advanced stage malignancy upon presentation for bothmale and female AA patients. Furthermore, a statistically
significant trend for later stage at presentation was ob-
served by age of Medicare eligibility (i.e., <65 vs. ≥65).
While smoking causes all types of lung cancer, the percent-
age of cases attributable to smoking varies by histology,
with squamous and small cell carcinomas conveying the
greatest risk (Khuder 2001; Barbone et al. 1997; Boffetta
et al. 2011). However, AAs in our study presented with
more advanced stage lung cancer than whites, regardless of
smoking-related histology.
Currently, no recommendations exist to effectively screen
for lung cancer by race in the general population (Detterbeck
et al. 2013; U.S. Preventive Services Task Force 2014; Aberle
et al. 2013). The “fundamental cause of disease approach”
argues that when no basic screening tool exists, racial differ-
ences in early detection and disease severity at presentation
may be less pronounced (Kim et al. 2010). However, we
observed that AA patients presented with more advanced
stage lung cancer overall and within insurance type com-
pared with whites. An effective screening tool, if it were to
exist for AAs, likely would magnify this observed health dis-
parity. Accordingly, AAs constitute a high-risk group who
should be appropriately targeted for screening as new and ef-
fective technologies for identifying lung cancer are developed
and made available (Gareen et al. 2014; Black et al. 2014).










n (%) n (%) n (%) n (%)
Males (n = 1,472) <0.0001 <0.0001 0.0005
White 268 (72) 119 (78) 251 (64) 343 (61)
AA 102 (28) 33 (22) 139 (36) 217 (39)
Females (n = 879) 0.0009 0.0010 0.0030
White 199 (80) 72 (82) 157 (73) 225 (69)
AA 50 (20) 16 (18) 57 (27) 103 (31)
Age < 65 (n = 1,008) 0.0040 0.0147 0.0140
White 142 (67) 73 (78) 176 (63) 247 (58)
AA 69 (33) 21 (22) 104 (37) 176 (42)
Age≥ 65 (n = 1,343) <0.0001 0.0001 0.0001
White 325 (80) 118 (81) 232 (72) 321 (69)
AA 83 (20) 28 (19) 92 (28) 144 (31)
Higher smoking risk (n = 978)˄ 0.0013 0.0011 0.0015
White 217 (79) 98 (83) 181 (68) 222 (70)
AA 58 (21) 20 (17) 85 (32) 97 (30)
Lower smoking risk (n = 1,373)˅ <0.0001 0.0001 0.0011
White 250 (73) 93 (76) 227 (67) 346 (61)
AA 94 (27) 29 (24) 111 (33) 223 (39)
˄Squamous cell carcinoma, small cell lung carcinoma (SCLC).
˅Adenocarcinoma, large cell neuroendocrine carcinoma (LCNEC), bronchoalveolar, non-small-cell lung carcinoma not otherwise specified (NSCLC NOS), other
histology. AA = African-American
†Exact Cochran-Armitage trend test.
§Likelihood ratio trend test.
¥Adjusted for sex and smoking-related histology, unless a stratifying variable.
₰Adjusted for age (continuous), sex and smoking-related histology, unless a stratifying variable.
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tion in eastern North Carolina allowed for us to report
on a group that has experienced historic differences in
access to care and discrimination. Ninety percent of the
counties in this region have a higher percentage of AAs
than the national value of 13.1% (United States Census
Bureau 2010; Efird et al. 2013). Our rural catchment area
represents a unique population regarding health care re-
sources. For example, residents of rural regions have lim-
ited access to medical providers compared with urban
areas (Shugarman and Farley 2003; Pathman et al. 2006).
Data also were collected from a population-based cancer
registry with a standardized data entry system and routine
quality control.
This study was limited by the incompleteness of some
variables (n = 45, tobacco use; n = 21, payor status).
However, the relative imputation efficiency for these var-
iables exceeded 99.8% and it is unlikely that this would
have biased our results. Important pieces of information
that would have been useful in the etiologic and ex-
planatory interpretation of the study findings (e.g., in-
come, education and occupation, individual-level SES,marital status, evidence of doctor’s or emergency room
visits within the year prior to cancer diagnosis, percent-
age of patients with an x-ray obtained within 6 months
prior to diagnosis, pack years smoked, and age of first
tobacco use) were not available in the current analysis.
Ideally, future studies will be designed to collect this
information.
Our analysis by insurance type and stage resulted in
small sample sizes within groups. Insurance status was
recorded at the time of diagnosis and it also is possible
that Medicaid was retroactively granted to uninsured or
underinsured patients as a result of diagnosis. The latter
limitation may have resulted in misclassification and se-
lection bias. Self-reports of tobacco use have been shown
to be lower than actual use, especially among AA pa-
tients (Gorber et al. 2009; Corral et al. 2013; Fisher et al.
2008), and the tobacco products that AAs are more
likely than whites to smoke (i.e., cigarillos) rarely are
assessed (Corral et al. 2013). The reporting of tobacco
use is a sensitive and potentially stigmatizing topic and
some patients may have been reluctant to report usage
truthfully. However, any resulting bias likely had a










n (%) n (%) n (%) n (%)
All insurance types <0.0001 <0.0001 <0.0001
White 467 (75) 191 (80) 408 (68) 568 (64)
AA 152 (25) 49 (20) 196 (32) 320 (36)
Medicare w/o supplement 0.0079 0.014 0.015
White 129 (67) 47 (64) 107 (58) 141 (55)
AA 64 (33) 26 (36) 78 (42) 115 (45)
Medicare with supplement 0.011 0.013 0.016
White 156 (88) 59 (84) 118 (80) 178 (79)
AA 21 (12) 11 (16) 29 (20) 48 (21)
Medicaid 0.48 0.55 0.44
White 22 (48) 11 (69) 19 (41) 40 (45)
AA 24 (52) 5 (31) 27 (59) 49 (55)
Private insurance 0.049 0.10 0.14
White 149 (80) 68 (92) 139 (78) 174 (74)
AA 38 (20) 6 (8) 39 (22) 62 (22)
No insurance/self-pay 0.016 0.047 0.049
White 11 (69) 6 (86) 25 (52) 35 (43)
AA 5 (31) 1 (14) 23 (48) 46 (57)
†Exact Cochran-Armitage trend test.
§Likelihood ratio trend test.
¥Adjusted for sex and smoking-related histology.
₰Adjusted for age (continuous), sex and smoking-related histology.
AA = African-American.
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lung cancer patients have a history of tobacco use. The
absence of individual and area-level socioeconomic mea-
sures was another potential limitation of our analyses.
The results of this study are from a rural region with a
unique population and may not generalize to other areas
of the country. However, because our data were col-
lected from one health system, this might have partially
controlled for other healthcare-related factors (e.g., vari-
ation in misclassification of staging system and payor
status, as well as geography). Furthermore, we were un-
able to reliably estimate socioeconomic position using
zip codes because a large percentage of patients in our
region have postal box addresses. However, eastern
North Carolina is relatively homogenous with respect to
socioeconomic status and it is unlikely that inclusion of
this variable in our models would have substantively
changed the results of this study.
Conclusions
Equality in health insurance (a crude measure of access
to care) may not ensure equal presentation of stage be-
tween AA and white lung cancer patients. Furtherresearch is needed to identify the underlying determi-
nants and appropriate measures for ameliorating this
disparity.
Methods
Patients and clinical variables
Patients who were diagnosed with lung cancer between
2001 and 2010 at the Leo Jenkins Cancer Center, East
Carolina University were included in this study. Ap-
proval for the study was obtained from the Institutional
Review Board at the Brody School of Medicine.
Methodology for data collection has been previously
described (Biswas et al. 2014; Elchoufani et al. 2013).
Briefly, data were obtained from the Vidant Medical
Center Cancer Registry, which includes patients seen at
Vidant Medical Center, Brody School of Medicine, Physi-
cians East, SurgiCenter, and other local medical clinics.
The registry follows standard data collection and validation
procedures and has received the Commission on Cancer
Outstanding Achievement Award from the American
College of Surgeons. When necessary, information in
our tumor registry was verified by cross-linkage with
administrative billing records.
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race, stage, histology, tobacco use, and treatment history
(surgery, chemotherapy, and radiation therapy according
to current standards of practice). Lung cancer was cate-
gorized into 7 groups based on pathology reports and in-
cluded SCC, adenocarcinoma, NSCLC NOS, SCLC,
large cell neuroendocrine carcinoma (LCNEC), broncho-
alveolar carcinoma, and other histology. Histology was
stratified by high (SCC, SCLC) and low (adenocarcin-
oma, LCNEC, bronchoalveolar, NSCLC NOS, other)
smoking risk (Khuder 2001; Barbone et al. 1997; Boffetta
et al. 2011). Tumor stage at initial diagnosis/presentation
was categorized according to criteria established by the
American Joint Committee on Cancer (AJCC). Health
insurance coverage was determined at the time of diagno-
sis and defined as Medicare with and without supplement,
Medicaid, private, and no insurance/self-pay. Insurance
was coded as a single variable field. Individuals with Medi-
care may have had supplemental insurance, and this was
coded as a separate category from Medicare without sup-
plement. Because of small numbers, patients with TriCare
(n = 26) or Veteran’s Affairs insurance (n = 3) were recoded
as private insurance and Medicare without supplement, re-
spectively. Tobacco use was self-reported and included
cigarette, cigar, pipe, and smokeless tobacco (snuff, chew)
use. Similarly, information on age, sex, and race was pro-
vided by the patient.
Statistical analysis
Categorical variables were reported as frequency and per-
centage while continuous variables were reported as mean, ±
standard deviation, median, and interquartile range.
Statistical significance for categorical variables was tested
using the Fisher’s exact test and the Deuchler-Wilcoxon
procedure for continuous variables. Relative risks with
95% confidence intervals (CI) were used as the measure of
association between predictor variables and stage at pres-
entation (III/IV versus I/II) and were computed using a
robust Poisson regression model. Trend across levels of
stage by race was assessed using the exact Cochran-
Armitage or likelihood ratio test for trend.
An iterative expectation-maximization (EM) algorithm
was used to impute missing values (Dempster et al.
1977; Little et al. 2012; Ware et al. 2012). The relative ef-
ficiency for each imputed variable (tobacco use, insur-
ance type) exceeded 99.8%. Model goodness of fit was
assessed using the Hosmer-Lemeshow test (Hosmer and
Lemeshow 2000). Rounding was performed using the
method of Holly and Whittemore (Holly et al. 1989).
Statistical significance was defined as p < 0.05. SAS
Version 9.4 (Cary, NC) was used for all analyses.
Abbreviations
AA: African-American; AJCC: American Joint Committee on Cancer;
CI: Confidence intervals; EM: Expectation-maximization; IQR: Interquartile range;LCNEC: Large cell neuroendocrine carcinoma; NSCLC NOS: Non-small cell lung
carcinoma not otherwise specified; RR: Relative risk; SCLC: Small cell lung
carcinoma; SD: Standard deviation; SES: Socioeconomic status; SCC: Squamous
cell carcinoma.
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